PRKAA2 and neoplasm: We observed significantly smaller tumors in Treg cell–specific AMPKα1-deficient mice relative to controls, while those with AMPKα2-deficient Treg cells exhibited significantly greater tumor volume over time through day 15 after tumor engraftment, relative to mice bearing control, AMPKα1-, and AMPKα1/α2–deficient Treg cells (Supplemental Figure 4, A and B).